ClinicalTrials.gg
Active, not recruitingNCT06858618Updated Mar 5, 2025

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

A Phase 2 interventional study of FCN-338 + Azacitidine and FCN-338 + erythromycin+ Ara-C in Safety, Antitumor Activity and PK Profile, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Aug 2023, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Enrollment
113th of 211
47 · median 50
Started
2023
with 9 others
Phase 2
105 of 214
40 open now
Primary completion
2026-12
later than 21 of 90 live
Registered
181st of 214
by date

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 113th largest by enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2023, is one of 105 in phase 2, reaches primary completion later than 21 of the 90 other live ones, and was the 181st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, multicenter study to safety \& tolerability, antitumor activity, and pharmacokinetics of FCN-338 in Combination with szacitidine (AZA) or chemotherapy(erythromycin, cytarabine(Ara-C)) in Patients with myeloid neoplasms

Read the detailed description

Primary Objectives:1.To assess the safety and tolerability of FCN-338 in combination with AZA or chemotherapy in patients with myeloid neoplasms. 2. To explore the antitumor activity of FCN-338 combination therapy in patients with myeloid neoplasms.

Secondary Objectives: 1. To assess the pharmacokinetic profile of the FCN-338 combination therapy in patients with myeloid neoplasms.2. To assess the transfusion independence rate in patients with myeloid neoplasms.

There were 2 cohorts based on different combination therapies and different indications.

Cohort A is FCN-338 combined with AZA (75mg/m², SC, QD, D1-7) for the treatment in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

Cohort B is FCN-338 combined with intensive chemotherapy for first line (1L) fit AML patients. During the induction phase, patients will be treated with erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7). Patients achieving partial remission (PR) will repeat induction phase once, and patients who do not reach PR after first cycle of induction phase and those who do not achieve complete remission (CR)/Complete remission with incomplete hematological recovery (CRi)/morphologic leukemia-free state (MLFS) after two cycles of induction phase will receive other new antitumor treatments. Patients who achieve CR/CRi/MLFS will undergo consolidation phase with medium- to high-dose Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles, with the exact dose and number of cycles determined by investigator. Patients with intermediate- to high-risk according to the 2017 European Leukemia Net (ELN) stratification will undergo a total of 24 cycles of maintenance phase after completion of consolidation phase. Maintenance phase will consist of 24 cycles, FCN-338 in combination with AZA (50 mg/m², d1-5) for the first 12 cycles and FCN-338 alone for the rest 12 cycles. FCN-338 will be administered once daily (QD), D1-14 per cycle during induction phase, consolidation phase and maintenance phase.

03

Conditions studied

  • Safety
  • Antitumor Activity
  • PK Profile

Keywords

  • BCL-2 inhibitor
  • Acute Myeloid Leukemia
  • safety
  • antitumor activity
  • PK profile
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusive Criteria

  1. Age ≥18 years.
  2. Cohort A: Patients diagnosed with R/RAML (≥5% blasts in the bone marrow) according to the WHO 2016 criteria [excluding acute promyelocytic leukemia (APL) and BCR-ABL positive AML], meeting any of the following definitions:
  1. AML: Reappearance of leukemic cells in peripheral blood or ≥5% blasts in bone marrow after complete remission (CR, CRi) (excluding other causes such as bone marrow regeneration after consolidation treatment) or infiltration of leukemic cells outside the marrow; 2) Refractory AML: Ineffective after two cycles of standard treatment; Relapsed within 12 months after CR followed by consolidation treatment; Relapsed after 12 months but ineffective with standard chemotherapy; Relapsed two or more times; With persistent extramedullary leukemia.
  1. Cohort B: Patients diagnosed with 1L fit AML according to the WHO 2016 criteria [excluding acute promyelocytic leukemia (APL) and BCR-ABL positive AML].
  1. (ECOG) performance status score of 0-2. 5. Expected survival time ≥ 3 months. 6. Adequate bone marrow and organ function. Exclusive Criteria
  1. Patients with diagnosis of APL or BCR-ABL-positive AML patients or a history of prior myeloproliferative disease (MPN).
  2. With known leukemic infiltration of the central nervous system.
  3. Have received hematopoietic stem cell transplantation or overt immune cell therapy, or autologous hematopoietic stem cell transplantation within 1 year.
  4. Have active fungal, bacterial and/or viral infections including, but not limited to, active (HIV), viral or C.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    relapse/refractory (R/R) AML

    Combination Product: FCN-338 + Azacitidine

  • Experimental
    1L fit AML

    Combination Product: FCN-338 + erythromycin+ Ara-C

Interventions

  • Combination productFCN-338 + Azacitidine

    Drug pages: Bcl-2 Inhibitor LOXO-338 · Azacitidine

    FCN-338 (400 or 600 mg, PO, QD, D1-28) combined with azacitidine (75mg/m², SC, QD, D1-7), 28 days/cycle

  • Combination productFCN-338 + erythromycin+ Ara-C

    Drug pages: Bcl-2 Inhibitor LOXO-338 · Erythromycin · Cytarabine

    Induction phase: FCN-338(600 mg, QD, D1-14) , erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7) for 1 to 2 cycles. Consolidation phase: FCN-338(600 mg, QD, D1-14) ,Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles Maintenance phase:FCN-338(600 mg, QD, D1-14) , azacitidine (50 mg/m², SC, QD, D1-5) for the first 12 cycles and FCN-338 (600 mg, QD, D1-14) alone for the rest 12 cycles

06

What researchers measure

Primary outcomes

  1. Incidence of DLT

    Incidence of DLT in DLT observation period

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Title: composite CR rate (CRc)

    The proportion of CR, CRi and MLFS patients in the efficacy analysis set (EAS)

    Time frame: From the first dose to the end of maintenance phase, assessed up to 30 months

  3. Minimal residual disease (MRD) negative rate

    The proportion of AML patients with CR/CRi/MLFS who were negative for MRD.

    Time frame: From the first dose to the end of maintenance phase, assessed up to 30 months

Secondary outcomes

  1. Transfusion Independence

    The proportion of independence on red blood cell (RBC) and platelet transfusions among those patients who were dependent on RBC and platelet transfusions at baseline.

    Time frame: From the first dose to the end of maintenance phase, assessed up to 30 months

  2. Time to remission

    Defined as the time from the first dose to the first observation of CR/CRi/MLFS

    Time frame: From the first dose to the first observation of CR/CRi/MLFS, assessed up to 2 months

  3. Event-free survival

    Defined as the time from the first dose to induction failure or relapse or death from any cause (whichever occours first).

    Time frame: From the first dose to induction failure or relapse or death from any cause (whichever occours first), assessed up to 54 months

  4. Duration of remission

    Defined as the time from the first observation of CR/CRi/MLFS to tumor progression or death from any cause(whichever occours first).

    Time frame: From the first observation of CR/CRi/MLFS to tumor progression or death from any cause(whichever occours first), assessed up to 54 months

  5. Overall survival

    Defined as the time from the first dose to death from any cause.

    Time frame: From the first dose to 30 days after the last dose or the initiation of new antitumor therapy (whichever occours first), assessed up to 30 months

  6. Incidence of treatment-emergent adverse events(TEAEs) and treatment-related adverse events (TRAEs) [Safety and Tolerability]

    Safety will be evaluated by summarizing DLT, AE, changes in laboratory findings, and changes in vital signs. Adverse events will be summarized for the DLT observation period and the entire treatment period based on the DLT analysis set and the safety analysis set, respectively, and drug-related AEs, SAEs, AEs of toxicity grade ≥3, and AEs leading to discontinuation will be counted. The occurrence of DLT will be assessed specifically for the DLT analysis set.

    Time frame: From the first dose to 30 days after the last dose or the initiation of new antitumor therapy (whichever occours first).

  7. Cmax of FCN-338

    Pharmacokinetics of FCN-338 by assesment of the maximum plasma concentration

    Time frame: Up to 24 hours postdose

  8. AUC0-t of FCN-338

    Pharmacokinetics of FCN-338 by assesment of the Area Under The Plasma Concentration Time Curve From Time 0 To The Time Of The Last Quantifiable Concentration

    Time frame: Up to 24 hours postdose

  9. AUC0-24 of FCN-338

    Pharmacokinetics of FCN-338 by assesment of the Area Under The Plasma Concentration Time Curve From Time 0 To The 24 hours postdose

    Time frame: Up to 24 hours postdose

  10. AUC0-∞ of FCN-338

    Pharmacokinetics of FCN-338 by assesment of The Plasma Concentration Time Curve From Time 0 To Infinity

    Time frame: Up to 24 hours postdose

  11. Tmax of FCN-338

    Pharmacokinetics of FCN-338 by assesment of Time To Maximum Observed Plasma Concentration

    Time frame: Up to 24 hours postdose

  12. t1/2 of FCN-338

    Pharmacokinetics of FCN-338 by assesment of Terminal Half-life

    Time frame: Up to 24 hours postdose

  13. CL/F of FCN-338

    Pharmacokinetics of FCN-338 by assesment of Apparent Clearance Of Drug From Plasma After Oral Administration

    Time frame: Up to 24 hours postdose

  14. Vd/F of FCN-338

    Pharmacokinetics of FCN-338 by assesment of Apparent Volume Of Distribution

    Time frame: Up to 24 hours postdose

  15. Css_max of FCN-338

    Pharmacokinetics of FCN-338 by assesment of Maximum Observed Plasma Concentration At Steady State

    Time frame: Up to 24 hours postdose

  16. Css_av of FCN-338

    Pharmacokinetics of FCN-338 by assesment of the Average concentration At Steady State

    Time frame: Up to 24 hours postdose

  17. AUCss of FCN-338

    Pharmacokinetics of FCN-338 by assesment of the Area Under The Plasma Concentration Time Curve within dosing interval At Steady State

    Time frame: Up to 24 hours postdose

  18. DF of FCN-338

    Pharmacokinetics of FCN-338 by assesment of fluctuation

    Time frame: Up to 24 hours postdose

  19. MRT

    Pharmacokinetics of FCN-338 by assesment of Mean residence time

    Time frame: Up to 24 hours postdose

  20. Kel of FCN-338

    Pharmacokinetics of FCN-338 by assesment of the Terminal rate constant.

    Time frame: Up to 24 hours postdose

  21. Css_min of FCN-338

    Pharmacokinetics of FCN-338 by assesment of Trough Concentration At Steady State

    Time frame: Up to 24 hours postdose

07

Study locations

1 site
  • Union hospital tongjimedical college huzhong university of science and technology
    Wuhan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's planned 39 months is close to that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Mar 5, 2025
StartActual
Aug 16, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06858618
Collaborators
Beijing Fosun Pharmaceutical Technology Development Co., Ltd.
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Aug 16, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bcl-2 Inhibitor LOXO-338 · Azacitidine · Erythromycin · Cytarabine

Start the discussion